Developing long-acting injections to prevent and treat tuberculosis
Harnessing potent next-generation diarylquinolines for long-acting injectable formulations to prevent and treat tuberculosis
This study is looking at new long-lasting injections to help prevent and treat tuberculosis (TB) in people living with HIV, making it easier for them by reducing the need for daily pills.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-11081969 on NIH RePORTER |
What this research studies
This research focuses on creating long-acting injectable formulations of next-generation diarylquinolines to improve the prevention and treatment of tuberculosis (TB), particularly in individuals living with HIV. The goal is to simplify treatment regimens, which currently require daily pills for extended periods, by providing an injectable option that could enhance adherence and reduce the burden of daily medication. The study will evaluate the effectiveness of these new formulations in preventing and treating TB, aiming to improve patient outcomes and public health responses.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals living with HIV who are at risk of or currently have tuberculosis.
Not a fit: Patients who do not have HIV or tuberculosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and easier treatment options for tuberculosis, particularly for those living with HIV.
How similar studies have performed: Previous research has shown promise with similar long-acting injectable formulations, indicating potential for success in this area.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Nuermberger, Eric L — Johns Hopkins University
- Study coordinator: Nuermberger, Eric L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.